These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 33669698)
21. Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer. Cossu-Rocca P; Orrù S; Muroni MR; Sanges F; Sotgiu G; Ena S; Pira G; Murgia L; Manca A; Uras MG; Sarobba MG; Urru S; De Miglio MR PLoS One; 2015; 10(11):e0141763. PubMed ID: 26540293 [TBL] [Abstract][Full Text] [Related]
22. Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer. Bhat-Nakshatri P; Goswami CP; Badve S; Magnani L; Lupien M; Nakshatri H Cancer Res; 2016 Jul; 76(13):3989-4001. PubMed ID: 27197157 [TBL] [Abstract][Full Text] [Related]
23. FOXK1 promotes malignant progression of breast cancer by activating PI3K/AKT/mTOR signaling pathway. Li ZQ; Qu M; Wan HX; Wang H; Deng Q; Zhang Y Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9978-9987. PubMed ID: 31799667 [TBL] [Abstract][Full Text] [Related]
24. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma. Rahman M; Nakayama K; Rahman MT; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K Hum Pathol; 2012 Dec; 43(12):2197-206. PubMed ID: 22705003 [TBL] [Abstract][Full Text] [Related]
25. Identification of mutations in the PI3K-AKT-mTOR signalling pathway in patients with macrocephaly and developmental delay and/or autism. Yeung KS; Tso WWY; Ip JJK; Mak CCY; Leung GKC; Tsang MHY; Ying D; Pei SLC; Lee SL; Yang W; Chung BH Mol Autism; 2017; 8():66. PubMed ID: 29296277 [TBL] [Abstract][Full Text] [Related]
26. Functional analysis of non-hotspot AKT1 mutants found in human breast cancers identifies novel driver mutations: implications for personalized medicine. Yi KH; Axtmayer J; Gustin JP; Rajpurohit A; Lauring J Oncotarget; 2013 Jan; 4(1):29-34. PubMed ID: 23237847 [TBL] [Abstract][Full Text] [Related]
27. Activation of PI3K/Akt/mTOR pathway and dual inhibitors of PI3K and mTOR in endometrial cancer. Chen J; Zhao KN; Li R; Shao R; Chen C Curr Med Chem; 2014; 21(26):3070-80. PubMed ID: 24735369 [TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma. Tasioudi KE; Sakellariou S; Levidou G; Theodorou D; Michalopoulos NV; Patsouris E; Korkolopoulou P; Saetta AA APMIS; 2015 Aug; 123(8):639-47. PubMed ID: 25912437 [TBL] [Abstract][Full Text] [Related]
29. Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer. De Marco C; Laudanna C; Rinaldo N; Oliveira DM; Ravo M; Weisz A; Ceccarelli M; Caira E; Rizzuto A; Zoppoli P; Malanga D; Viglietto G PLoS One; 2017; 12(6):e0178865. PubMed ID: 28662101 [TBL] [Abstract][Full Text] [Related]
30. Single-cell RNA sequencing reveals the mechanism of PI3K/AKT/mTOR signaling pathway activation in lung adenocarcinoma by KRAS mutation. Xu L; Ding R; Song S; Liu J; Li J; Ju X; Ju B J Gene Med; 2024 Jan; 26(1):e3658. PubMed ID: 38282149 [TBL] [Abstract][Full Text] [Related]
31. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts. Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320 [TBL] [Abstract][Full Text] [Related]
32. KRAS gene silencing inhibits the activation of PI3K-Akt-mTOR signaling pathway to regulate breast cancer cell epithelial-mesenchymal transition, proliferation and apoptosis. Zhang Y; Liu JL; Wang J Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3085-3096. PubMed ID: 32271426 [TBL] [Abstract][Full Text] [Related]
33. The PI3K/AKT/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis. Zhang X; Wu Y; Sun X; Cui Q; Bai X; Dong G; Gao Z; Wang Y; Gao C; Sun S; Ji N; Liu Y BMC Cancer; 2022 Feb; 22(1):190. PubMed ID: 35184749 [TBL] [Abstract][Full Text] [Related]
34. The Gene Expression Status of the PI3K/AKT/mTOR Pathway in Gastric Cancer Tissues and Cell Lines. Riquelme I; Tapia O; Espinoza JA; Leal P; Buchegger K; Sandoval A; Bizama C; Araya JC; Peek RM; Roa JC Pathol Oncol Res; 2016 Oct; 22(4):797-805. PubMed ID: 27156070 [TBL] [Abstract][Full Text] [Related]
35. Mutation Profiling of Usual Ductal Hyperplasia of the Breast Reveals Activating Mutations Predominantly at Different Levels of the PI3K/AKT/mTOR Pathway. Jahn SW; Kashofer K; Thüringer A; Abete L; Winter E; Eidenhammer S; Viertler C; Tavassoli F; Moinfar F Am J Pathol; 2016 Jan; 186(1):15-23. PubMed ID: 26718977 [TBL] [Abstract][Full Text] [Related]
36. Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 Positive Feedback Loop Induces Cell Cycle Arrest by Dual PI3K/mTOR Inhibitor PQR309 in Endometrial Cancer Cell Lines. Hsin IL; Shen HP; Chang HY; Ko JL; Wang PH Cells; 2021 Oct; 10(11):. PubMed ID: 34831139 [TBL] [Abstract][Full Text] [Related]
37. Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations. Hafner C; Landthaler M; Vogt T Exp Dermatol; 2010 Aug; 19(8):e222-7. PubMed ID: 20557351 [TBL] [Abstract][Full Text] [Related]
38. Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis. Umemura S; Mimaki S; Makinoshima H; Tada S; Ishii G; Ohmatsu H; Niho S; Yoh K; Matsumoto S; Takahashi A; Morise M; Nakamura Y; Ochiai A; Nagai K; Iwakawa R; Kohno T; Yokota J; Ohe Y; Esumi H; Tsuchihara K; Goto K J Thorac Oncol; 2014 Sep; 9(9):1324-31. PubMed ID: 25122428 [TBL] [Abstract][Full Text] [Related]
39. YBX1/lncRNA SBF2-AS1 interaction regulates proliferation and tamoxifen sensitivity via PI3K/AKT/MTOR signaling in breast cancer cells. Hussain SA; Venkatesh T Mol Biol Rep; 2023 Apr; 50(4):3413-3428. PubMed ID: 36754932 [TBL] [Abstract][Full Text] [Related]
40. Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression. Polo ML; Riggio M; May M; Rodríguez MJ; Perrone MC; Stallings-Mann M; Kaen D; Frost M; Goetz M; Boughey J; Lanari C; Radisky D; Novaro V Oncotarget; 2015 Sep; 6(26):22081-97. PubMed ID: 26098779 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]